Literature DB >> 31381461

Immunohistochemical Expression of Somatostatin Receptor Subtypes in a Panel of Neuroendocrine Neoplasias.

Satu M Remes1, Helena L Leijon1, Tiina J Vesterinen1,2, Johanna T Arola1, Caj H Haglund3,4.   

Abstract

Neuroendocrine neoplasias (NENs) are known to express somatostatin receptors (SSTRs) 1-5, which are G-protein-coupled cell membrane receptors. Somatostatin receptor imaging and therapy utilizes the SSTR expression. Synthetic somatostatin analogs with radioligands are used to detect primary tumors, metastases, and recurrent disease. Receptor analogs are also used for treating NENs. Furthermore, commercially available SSTR antibodies can be used for the immunohistochemical (IHC) detection of SSTRs. We investigated different SSTR antibody clones applying diverse IHC protocol settings to identify reliable clones and feasible protocols for NENs. A tissue microarray including NENs from 12 different primary sites were stained. Only UMB clones were able to localize SSTR on the cell membranes of NENs. SSTR2 (UMB1) emerged as the most common subtype followed by SSTR5 (UMB4) and SSTR1 (UMB7). SSTR3 (UMB5) expression was mainly cytoplasmic. Yet, SSTR4 expression was weak and located primarily in the cytoplasm. Thus, appropriate IHC protocols, including proper positive and negative controls, represent requirements for high-quality NEN diagnostics and for planning personalized therapy.

Entities:  

Keywords:  immunohistochemistry; neuroendocrine tumor; somatostatin receptor

Year:  2019        PMID: 31381461      PMCID: PMC6764062          DOI: 10.1369/0022155419856900

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  25 in total

1.  Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography.

Authors:  Meike Körner; Véronique Eltschinger; Beatrice Waser; Agnes Schonbrunn; Jean Claude Reubi
Journal:  Am J Surg Pathol       Date:  2005-12       Impact factor: 6.394

2.  Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis.

Authors:  U Kumar; R Sasi; S Suresh; A Patel; M Thangaraju; P Metrakos; S C Patel; Y C Patel
Journal:  Diabetes       Date:  1999-01       Impact factor: 9.461

3.  Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues.

Authors:  Jean Claude Reubi
Journal:  Endocrine       Date:  2014-06-10       Impact factor: 3.633

Review 4.  Neuroendocrine neoplasms and somatostatin receptor subtypes expression.

Authors:  Jerzy Hankus; Romana Tomaszewska
Journal:  Nucl Med Rev Cent East Eur       Date:  2016

5.  Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies.

Authors:  H Kulaksiz; R Eissele; D Rössler; S Schulz; V Höllt; Y Cetin; R Arnold
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

6.  Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1.

Authors:  Thomas Fischer; Christian Doll; Stefan Jacobs; Angela Kolodziej; Ralf Stumm; Stefan Schulz
Journal:  J Clin Endocrinol Metab       Date:  2008-08-12       Impact factor: 5.958

7.  Reevaluation of sst₁ somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7.

Authors:  Amelie Lupp; Falko Nagel; Stefan Schulz
Journal:  Regul Pept       Date:  2013-03-04

Review 8.  Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy.

Authors:  Deborah Pencharz; Gopinath Gnanasegaran; Shaunak Navalkissoor
Journal:  Br J Radiol       Date:  2018-09-12       Impact factor: 3.039

9.  Controls for immunohistochemistry: the Histochemical Society's standards of practice for validation of immunohistochemical assays.

Authors:  Stephen M Hewitt; Denis G Baskin; Charles W Frevert; William L Stahl; Eduardo Rosa-Molinar
Journal:  J Histochem Cytochem       Date:  2014-07-14       Impact factor: 2.479

10.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Authors:  Guido Rindi; David S Klimstra; Behnoush Abedi-Ardekani; Sylvia L Asa; Frederik T Bosman; Elisabeth Brambilla; Klaus J Busam; Ronald R de Krijger; Manfred Dietel; Adel K El-Naggar; Lynnette Fernandez-Cuesta; Günter Klöppel; W Glenn McCluggage; Holger Moch; Hiroko Ohgaki; Emad A Rakha; Nicholas S Reed; Brian A Rous; Hironobu Sasano; Aldo Scarpa; Jean-Yves Scoazec; William D Travis; Giovanni Tallini; Jacqueline Trouillas; J Han van Krieken; Ian A Cree
Journal:  Mod Pathol       Date:  2018-08-23       Impact factor: 7.842

View more
  9 in total

1.  Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.

Authors:  Max Czajkowski; Daniel Kaemmerer; Jörg Sänger; Guido Sauter; Ralph M Wirtz; Stefan Schulz; Amelie Lupp
Journal:  BMC Cancer       Date:  2022-07-07       Impact factor: 4.638

Review 2.  Somatostatin receptor radionuclide therapy in neuroendocrine tumors.

Authors:  Mintallah Haider; Satya Das; Taymeyah Al-Toubah; Eleonora Pelle; Ghassan El-Haddad; Jonathan Strosberg
Journal:  Endocr Relat Cancer       Date:  2021-03       Impact factor: 5.678

3.  SSTR2 Expression in Olfactory Neuroblastoma: Clinical and Therapeutic Implications.

Authors:  Vincent Cracolici; Eric W Wang; Paul A Gardner; Carl Snyderman; Stacey M Gargano; Simion Chiosea; Aatur D Singhi; Raja R Seethala
Journal:  Head Neck Pathol       Date:  2021-04-30

4.  Correlation of Somatostatin Receptor 1-5 Expression, [68Ga]Ga-DOTANOC, [18F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms.

Authors:  Susanna Majala; Tiina Vesterinen; Hanna Seppänen; Harri Mustonen; Jari Sundström; Camilla Schalin-Jäntti; Risto Gullichsen; Jukka Schildt; Jukka Kemppainen; Johanna Arola; Saila Kauhanen
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

Review 5.  Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.

Authors:  Maria I Del Olmo-García; Stefan Prado-Wohlwend; Pilar Bello; Angel Segura; Juan F Merino-Torres
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

Review 6.  Role of Somatostatin Signalling in Neuroendocrine Tumours.

Authors:  Olesja Rogoza; Kaspars Megnis; Marija Kudrjavceva; Aija Gerina-Berzina; Vita Rovite
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

7.  Reassessment of SST4 Somatostatin Receptor Expression Using SST4-eGFP Knockin Mice and the Novel Rabbit Monoclonal Anti-Human SST4 Antibody 7H49L61.

Authors:  Amelie Lupp; Blanca Ehms; Ralf Stumm; Johannes Göckeritz; Christian Mawrin; Stefan Schulz
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

8.  Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET/CT.

Authors:  Andreas K Buck; Rudolf A Werner; Sebastian E Serfling; Constantin Lapa; Niklas Dreher; Philipp E Hartrampf; Steven P Rowe; Takahiro Higuchi; Andreas Schirbel; Alexander Weich; Stefanie Hahner; Martin Fassnacht
Journal:  Mol Imaging Biol       Date:  2022-03-21       Impact factor: 3.484

9.  Reassessment of somatostatin receptor SST4 expression in bronchopulmonary and gastroenteropancreatic neuroendocrine neoplasms using the novel rabbit monoclonal anti-human SST4 antibody 7H49L61.

Authors:  Blanca Ehms; Daniel Kaemmerer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.